Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction
2016-002299-28Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Omecamtiv mecarbil with Placebo (2 arms). Primary endpoint: Time to cardiovascular death or first heart failure event. Started Sep 2016; status: completed.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2016-002299-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002299-28.